Dr Goranka Tanackovic
Chief Executive Officer; Boards of Directors
Dr Tanackovic obtained MSc degree in both Biology and Chemistry from the University of Osijek, Croatia. She then studied human hereditary disorders and, in 1999, earned PhD in Biology from the University of Zagreb, Croatia. In 2000 she moved to Geneva, Switzerland, where she worked in the filed of RNA research and was awarded her second PhD in Biology in 2004, from the University of Geneva. Her postdoctoral research at the University of Lausanne was focused on molecular mechanisms involved in various genetic diseases. During her academic career, Dr Tanackovic successfully led various research projects, obtained numerous research grants, and results of her work are recognized through the publications in high-impact per-reviewed journals.
In parallel with her PhD studies, Dr Tanackovic successfully completed entrepreneurship program of „Create“ Switzerland (2002) and was one of the winners of „Venture Leaders“ program in 2003. In this frame, she also successfully completed an entrepreneurship program at Babson College, Wellesley, US (2003).
She joined Gene Predictis as CEO in September 2011. She changed the vision and the strategy of the company with the buy-in of the board and the team. She recruited and built highly performing team committed to the new vision and strategy. Under her direction, the company developed first in class diagnostic products answering important medical needs (e.g. measuring the risk of thrombosis for women using contraceptive pills); developed business significantly; won numerous awards, among others in 2019 two awards from Global Health and Pharma (The Most Pioneering Precision Medicine Company – Europe & The Best Pharmacogenetics Product: Pill Protect).
Since 2017, Dr Tanackovic is also teaching courses on Personal genomics and predictive genetics for Certificate in Industrial Life Science (CILS) program of the University of Geneva.
She is passionate about translating progresses in scientific research into health-care solutions for patients and is determined to keep further developing Gene Predictis and make company’s proprietary tests become benchmark to tailor drug therapies based on the individual.